The Bio Report
Editing Away Autoimmunity at the HLA Source
Why It Matters
Autoimmune diseases affect millions and current treatments only manage symptoms, leaving many patients refractory. By correcting the root genetic trigger at the HLA level, Rheumagen’s approach could offer durable, curative outcomes and reduce reliance on lifelong biologics, reshaping therapeutic paradigms across a broad spectrum of immune disorders.
Key Takeaways
- •Rheumagen edits HLA DRB0401 allele to stop autoimmunity.
- •Anchor editing modifies position 82 across class II HLA.
- •One‑time outpatient stem‑cell edit avoids myeloablation.
- •Mouse studies show complete block of self‑antigen presentation.
- •Potential permanent cure for refractory rheumatoid arthritis patients.
Pulse Analysis
Human leukocyte antigens (HLA) are the immune system’s presentation gatekeepers, and specific HLA alleles drive many autoimmune disorders. Rheumagen’s lead program, RG0401, targets the DRB0401 allele—one of the strongest genetic risk factors for rheumatoid arthritis—by using CRISPR‑based gene editing to silence its ability to present self‑peptides. By correcting the root cause rather than dampening downstream inflammation, the approach promises a true disease‑modifying solution that could eliminate the need for lifelong biologics.
The company’s proprietary “anchor editing” strategy focuses on a conserved amino‑acid position (82) within the HLA class II peptide‑binding groove. Swapping this residue disrupts the allele’s antigen‑presentation capacity while leaving the remaining twelve HLA genes untouched, preserving overall immune competence. The edit is performed on autologous hematopoietic stem cells, which are then returned to the patient in a single outpatient infusion, eliminating the traditional myeloablative conditioning used in bone‑marrow transplants. This streamlined workflow reduces procedural risk, shortens recovery time, and makes the therapy scalable across multiple autoimmune indications.
Pre‑clinical data reinforce the platform’s promise: edited mice show a 100 % block of self‑antigen presentation and resistance to collagen‑induced arthritis, with protective effects transferable via bone‑marrow grafts. Given that roughly 60 % of rheumatoid arthritis patients remain unsatisfied with existing treatments, a durable, potentially permanent cure could reshape the market and lower payer burden. Rheumagen plans to enroll refractory RA patients in a first‑in‑human trial, leveraging the anchor edit as a platform‑wide IND that could accelerate development for other HLA‑linked diseases such as multiple sclerosis and type 1 diabetes.
Episode Description
Human leukocyte antigen, or HLA, genes, help the immune system tell the difference between the body’s own tissues and outside threats. In some people, certain versions of HLA genes mistakenly flag normal proteins as dangerous, which can push immune cells to attack joints, nerves, the gut, or other organs. Many autoimmune diseases are driven by changes in HLA genes. RheumaGen is developing a new kind of gene-editing treatment that aims to cure autoimmune diseases by going after one of their root genetic triggers. Instead of broadly weakening the immune system, the company’s goal is to switch off a single “bad” version of an immune gene while leaving the rest of the body’s defenses intact. We spoke to Richard Freed, CEO of RheumaGen, about the role of HLA genes in autoimmune diseases, how the company’s gene-editing therapies work, and its lead program in rheumatoid arthritis.
Comments
Want to join the conversation?
Loading comments...